Home
Services
Immunization
Refill
Contact
About
0
Log In
FDA Drug Alerts
FDA DRUG ALERTS
FEB
05
Safety Labeling Update for Capecitabine and Fluorouracil (5-FU) on Risks Associated with Dihydropyrimidine Dehydrogenase (DPD) Deficiency
By:
on
FEB
05
Audience: Health Care Professional February 5, 2026 -- The U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU)...
Read more >>
JAN
13
FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications
By:
on
JAN
13
Audience: Health Care Professional, Consumer January 13, 2026 FDA Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With the Use of GLP-1 RA Medications This information is an update to the FDA Drug Safety...
Read more >>
JAN
09
Anthony Trinh, 123Herbals LLC (123HERBALS.COM) Issues Nationwide Recall of Silintan Capsules Due to the Presence of Undeclared Meloxicam
By:
on
JAN
09
Audience: Consumer January 09, 2026 -- Rosemead, CA, 01/07/2026 ANTHONY TRINH, 123herbals LLC is voluntarily recalling all lots of Silintan capsules to the consumer level. FDA analysis has found the product to be tainted with meloxicam. Meloxicam...
Read more >>
JAN
09
Modern Warrior Recalls “Modern Warrior Ready” Dietary Supplement Due to Undeclared 1,4-DMAA and Aniracetam, as Well as Tianeptine, Which has Not Been Approved for Supplement Use by the FDA
By:
on
JAN
09
Audience: Consumer January 9, 2026 -- [Phoenix, Arizona 12/22/25] – Modern Warrior is voluntarily recalling all lots of Modern Warrior Ready, a dietary supplement sold directly to consumers, after regulatory testing identified the presence of...
Read more >>
DEC
19
FDA Safety Communication: Update on the Safety of Andexxa by AstraZeneca
By:
on
DEC
19
Audience: Patient, Health Care Professional, Pharmacy, Hematology December 19, 2025 -- ISSUE: Since approval, the FDA has received postmarketing safety data on thromboembolic events, including serious and fatal outcomes, in patients treated with...
Read more >>
DEC
16
MediNatura New Mexico, Inc. Expands Voluntary Nationwide Recall of ReBoost Nasal Spray and to include ClearLife Allergy Nasal Spray Due to Microbial Contamination
By:
on
DEC
16
Audience: Consumer December 16, 2025 – Albuquerque, New Mexico, MediNatura New Mexico, Inc. is voluntarily recalling all lots of ReBoost Nasal Spray to the consumer level. The product has been found to contain yeast/mold and microbial...
Read more >>
DEC
10
MediNatura New Mexico, Inc. Issues Voluntary Nationwide Recall of ReBoost Nasal Spray Due to Microbial Contamination
By:
on
DEC
10
Audience: Consumer December 10, 2025 – Albuquerque, New Mexico, MediNatura New Mexico, Inc. is voluntarily recalling one lot of ReBoost Nasal Spray to the consumer level. The product has been found to contain yeast/mold and microbial...
Read more >>
DEC
05
Novo Nordisk Warns Consumers About Counterfeit Ozempic (semaglutide) Injection 1 mg in the US
By:
on
DEC
05
Audience: Consumer PLAINSBORO, NJ, December 5, 2025 - FDA recently seized dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg distributed illegally outside of Novo Nordisk’s authorized supply chain. The US Food and Drug...
Read more >>
DEC
02
FDA Seizes 7-OH Opioids to Protect American Consumers
By:
on
DEC
02
Audience: Consumers December 2, 2025 -- The U.S. Food and Drug Administration, in coordination with the U.S. Department of Justice, announced today that the U.S. Marshals Service seized approximately 73,000 units of 7-hydroxymitragynine (7-OH)...
Read more >>
NOV
21
FDA Investigating Death Due to Neutralizing Antibodies to ADAMTS13 following Adzynma Treatment of Congenital Thrombotic Thrombocytopenic Purpura
By:
on
NOV
21
Audience: Health Care Professional FDA Safety Communication – November 21, 2025 Summary of the Issue Since approval, the Food and Drug Administration (FDA) has received postmarketing reports of neutralizing antibodies to ADAMTS13...
Read more >>
More Posts
To provide accessible care and better health to ALL members of our community.
SERVICES
P
rescription Drugs
Over the Counter Drugs
Vaccinations
Free Home Delivery
MTM
CRM
Business Hours
Mon - Fri
10:00 am
-
6:00 pm
Saturday
10:00 am
-
2:00 pm
Sunday
Closed
CONTACT
(609) 323-7503
ewingpharmacy@gmail.com
1400 Parkway Ave, A2
Ewing, NJ 08628
Copyright 2025 Ewing Pharmacy
Design and Managed by
Copyright 2025 Ewing Pharmacy
Design and Managed by
Share by:
Please ensure Javascript is enabled for purposes of
website accessibility